Osteosarcoma and Teriparatide?

  title={Osteosarcoma and Teriparatide?},
  author={Kristine D. Harper and John H. Krege and R Marcus and Bruce H Mitlak},
  journal={Journal of Bone and Mineral Research},
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
  • L. Pietrogrande
  • Medicine, Biology
    International journal of women's health
  • 2010
The effect on bone mineral density (BMD) was clearly demonstrated in the spine and also in the hip, and the effects on BMD increased progressively with treatment until 36 months, and after its discontinuation there was a clear decrease in BMD if no antiresorptive treatment was initiated.
Clinical update on teriparatide
An update on teriparatide is provided, focusing on its mechanism of action compared with other antiresorptive agents, indications, adverse effects, therapy duration, combination therapy, contraindications, and cost effectiveness.
Postmenopausal osteoporosis: Current and future treatment options
Antiresorptive agents are cost-effective for preventing fractures in women with osteoporosis, but they might not offer enough protection in high-risk populations, and there is a cost- effective place for an anabolic agent in the highest-risk patients.
Principles of Diagnosis and Treatment of Osteoporosis
Osteoporosis is a skeletal disorder defined by a propensity for low trauma fractures (fragility fractures) and low bone mineral density (BMD) and its impact is especially felt in aging populations although there is higher prevalence in Caucasians.
The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin
The discovery that osteolectin mediates part of the effect of parathyroid hormone (PTH) on bone formation identifies a new mechanism by which PTH acts and provides proof-of-principle that combinatorial use can increase osteogenesis.
Roles of Parathyroid Hormone-Related Protein (PTHrP) and Its Receptor (PTHR1) in Normal and Tumor Tissues: Focus on Their Roles in Osteosarcoma
A review of the latest research with PTHrP and PTHR1 in OS tumorigenesis and possible mechanistic pathways is discussed.
Bone Health and Osteoporosis Prevention and Treatment
Postmenopausal osteoporosis is a common condition and is associated with increased risk of fracture, including hip and vertebral fractures that in turn can have devastating consequences on morbidity
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.
Romosozumab is a novel, 12-month treatment option for postmenopausal women at high risk for osteoporotic fracture that both increases bone formation and decreases bone resorption.


Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose
It is demonstrated that treatment duration and administered dose are the most important factors in the teriparatide-induced bone tumors in rats.
Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety
The data suggest that the increased incidence of bone neoplasia in rats treated for 2 years is likely not predictive of an increased risk of bone cancer in skeletally mature adult humans being given PTH(1-34) for a limited period of time in the treatment of osteoporosis.
Teriparatide [Human PTH(1‐34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis
  • A. Tashjian, R. Gagel
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2006
The FDA approved teriparatide for treatment of osteoporosis in men and women but placed significant limitations on its application, including a 2-year period and exclusion of patients considered at high risk for osteosarcoma.
Initial experience with teriparatide in the United States*
No reports of pathology-confirmed osteosarcoma have been received for individuals who have been treated with teriparatide, either with the commercially available drug or in clinical trials, either in the setting of clinical trials or from marketed drug experience.
Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1‐34 in the Treatment of Osteoporosis in Men and Postmenopausal Women
  • A. Tashjian, B. Chabner
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2002
There are concerns, based on studies in rats, about the long-term clinical safety of PTH as a therapeutic agent, and the likely risk-to-benefit ratio for treatment of osteoporosis in humans with rhPTH(1-34).